Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
المؤلف الرئيسي: | Paul, Pulock |
---|---|
مؤلفون آخرون: | Azam,Faruque |
التنسيق: | أطروحة |
اللغة: | English |
منشور في: |
Brac University
2024
|
الموضوعات: | |
الوصول للمادة أونلاين: | http://hdl.handle.net/10361/23954 |
مواد مشابهة
-
Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
بواسطة: Rahman, Tasnim
منشور في: (2024) -
Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
بواسطة: Hoque, Ismoth Ara
منشور في: (2024) -
Pooled analysis of response rate and overall survival of Tyrosine Kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
بواسطة: Karim, Samia Binte
منشور في: (2024) -
Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
بواسطة: Flora, Sanzida Alam
منشور في: (2024) -
A review on targeted therapies for lung cancer
بواسطة: Ashraf, Anushey
منشور في: (2023)